JCEM: Incidence and clinical manifestations of chromoblastoma and sarcoma neuroglioblastoma

Chromoblastoma and acrylic neurocytoma (PPGL) are rare tumors that secrete cerium phenolamines, but recent studies have shown that their incidence is increasing.
, PPGL patients have pre-existing symptoms and high blood pressure, but available data on the clinical performance of PPGL patients come from referral centres.
recently, a study published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, is a population-based study designed to summarize the relevant time trends in clinical performance and morbidity in PPGL patients.
researchers conducted a retrospective queue study of 567 PPGL patients diagnosed in Denmark between 1977 and 2015 and collected clinical data from the medical records of a subgroup of 192 patients.
researchers calculated the age-standardized incidence (SIR) and prevalence rates of the population nationwide, and descriptively calculated the performance of subgroups based on clinical data.
THER for the disease increased from 1.4 per million people per year in 1977 (95% CI is 0.2-2.5) to 6.6 per million people per year (in 2015, 95% CI was 4.4-8.7), an increase of 4.8 times.
increase was mainly due to the accidental detection of tumors smaller than 4 cm and the diagnosis of patients over 50 years of age who did not have excessive symptoms or limited seizures of cerpamine.
December 31, 2015, PPGL had a prevalence rate of 64.4 per million inhabitants (95% CI of 57.7-71.2).
of the 192 clinical cases, 171 (89.1%) had single-sided chromoblastoma, while single-sided side-by-side side neuroblastomas (n=13,6.8%) and multi-flavoured PPGL (n=8,4.2%) were rare.
, the incidence of PPGL increased 4.8 times between 1977 and 2015.